Examining Atopic Dermatitis through the One Health concept

Spring Live Global Virtual Symposium

Wednesday April 17, 2024 – 3 to 5 pm (Zurich Time, CET)

The International Society of Atopic Dermatitis is interested in all aspects of this common and challenging disease and has decided to hold a 2 hours symposium.

Our Spring Live Global Virtual Symposium will cover a rather novel field: One Health, a concept at the crossroad of human, animal, and environmental health.

This concept is instrumental in the field of infectious diseases, especially to limit the dissemination of existing diseases and to prevent emerging pandemics. Changes in temperature and precipitation alter the distribution and behavior of disease vectors, leading to the spread of malaria, dengue fever and viral infections such as Zika. Food and water insecurity linked to climate change leads to malnutrition, food, and water-borne diseases, such as cholera and diarrhea.

For allergic diseases, there is some indication that the concept is applicable, e.g. the increase in carbon dioxide levels stimulates the growth of allergenic plants, which exacerbates allergies and asthma.

A good argument for this new concept is that predisposed humans and pet animals living in the same environment develop the same disease. Canine AD is a good model for AD in this context. The ISAD has already organized in 2021 together with the vet community a virtual symposium on Canine vs Human AD.

At the 2022 Davos Global Allergy Forum, atopic dermatitis (AD) was aptly described as the major gateway to allergy, which is closely dependent on our environment. However, addressing AD within the One Health context is something new. This virtual symposium aims at creating a brainstorming session around the applicability of One Health in AD research and discuss potential innovative preventive measures.

SESSION 1 / 03:00 pm ~ 04:15 pm
15 min. presentation each


Bernadette ABELA (Switzerland)
WHO Int., veterinary of One Health and related conditions at the Global WHO NTD program:

Dr Bernadette ABELA works in the Global Programme for the Control of Neglected Tropical Diseases (NTDs) of the World Health Organization (WHO) as the lead on neglected zoonotic diseases and One Health. She was a member of the core drafting group of the new NTD roadmap and is closely involved in advancing common areas of work with the tripartite partners FAO, WOAH, WHO and UNEP, other global actors in health and beyond.

Bernadette is a veterinary epidemiologist by training and previously worked in the WHO Department of Food Safety and Zoonoses, for the US Food and Drug Administration on antimicrobial resistance, for l’Institut de recherche pour le développement (IRD) in Cameroon on emergence novel viruses from the wild, the Food and Agriculture Organization of the U.N. on veterinary public health, and in clinical veterinary practice.

Presented with Dijana MINIĆ-PANTIC:
Background on the One Health concept, applicability to complex disorders

Alexander ZINK (Germany/Sweden):

Data mining at the crossroad of AD, allergy, climate

Jenni LEHTIMÄKI (Finland):

Dr. Jenni LEHTIMÄKI is working as a Senior Research Scientist at Finnish Environment Institute, Finland. She utilizes her background in ecology and evolutionary biology to understand associations between living environment, microbial exposures, and health. Her work relates to the biodiversity hypothesis, which is an extension of the hygiene hypothesis, suggesting that biodiversity loss increases the incidence of non-communicable diseases such as atopic dermatitis. She has discovered that the health of pet dogs tends to respond to environmental exposures similarly as the health of humans indicating that mammals have shared causes of health and disease. Dr. Lehtimäki has also studied the early-life microbial exposures in infants in relation to their later risk of asthma and allergic diseases.

Pet dogs and their owners share root causes of health and disease

Erica JENSEN-JAROLIM (Austria):

Erika JENSEN-JAROLIM, MD, is Clinical Immunologist, specialized in Allergology, and Professor at the Medical University Vienna, Austria.

She is Past-President of the Austrian Society for Allergology and Immunology (ÖGAI).

She completed her clinical trainings at the University Vienna, the University Hospital Copenhagen, Denmark, and Institute of Immunology, Bern, Switzerland, and habilitated at the Medical University Vienna in 1998.

She initiated the new field “AllergoOncology” in 2006, and chairs the AllergoOncology working group with over 1000 members in EAACI.

Aside AllergoOncology, Erika JENSEN-JAROLIM concentrates on molecular allergology and allergy management. Her scientific oeuvre [Jensen-Jarolim E] and [Jarolim E] comprises over 300 peer-reviewed publications.

2006-2011 she chaired the Institute for Pathophysiology and Allergy Research at the Medical University Vienna, and since 2012 is double appointed to the interuniversity Messerli Research Institute Vienna, which she chaired 2019-2020.

During her Editor-in-Chief-ship of the World Allergy Organization journal 2014-2022, the impact factor of this journal raised from zero to IF 5.516.

Today she leads several research laboratories, and she also sees patients in her private practice AllergyCare® at Döbling Private Clinic, Vienna.

Erika Jensen-Jarolim is entrepreneur and developer of a novel allergen-unspecific approach for dietary management of allergic / atopic inflammation. The lozenge immunoBON® is marketed by Biomedical International R+D, Vienna, Austria, of which she is CEO.

The farm effect and industrialization in allergy/AD

Claudia TRAIDL-HOFFMANN (Germany):

Planetary health and the case of AD

SESSION 2 / 04:15 pm ~ 05:00 pm


Johannes RING,
Alain TAÏEB,

Who can attend, how to register?

Our event is free and open to all.
All participants have to register online on our platform to get the link and attend via Zoom: